Cancer drugs Flashcards
methotrexate moa
folic acid analog that inhibits DHFR, decreasing DNA and protein synthesis
methotrexate toxicity
myelosuppression, reversible with leucovorin; macro vesicular fatty change in liver; mucositis, teratogenic
5-FU moa
pyrimidine analog bioactivated to 5F-dUMP, which covalently complexes folic acid; this inhibits thymidylate synthetase; decreasing DNA and protein synthesis
cytarabine moa
pyrimidien analog that inhibits DNA polymerase
5-FU toxicity
myelosuppression and photosensitivity; tx overdose with uridine;
cytarabine toxicity
leukopenia, thrombocytopenia, megaloblastic anemia,
azathioprine, 6-MP, and 6-TG moa
purine analogs; decrease de novo purine synthesis; activated by HGPRT and metabolized by xanthine oxidase
azathioprine, 6-MP, and 6-TG toxicity
bone marrow suppression, GI, and liver toxicity; increased toxicity with allopurinol
dactinomycin moa
intercalates in DNA
doxorubicin and daunorubicin moa
generation of free radicals, DNA intercalation
doxorubicin and daunorubicin toxicity
dilated cardiomyopathy; dexrazoxane used to prevent cardiotoxicity
belomycin moa
induces free radical formation which causes breaks in DNA strands
bleomycin toxicity
pulmonary fibrosis, skin changes, mucositis
cyclophosphamide and ifosfamide moa
covalently X-link (inter strand) DNA at guanine N-7; require bioactivation by liver
cyclophosphamide and ifosfamide toxicity
hemorrhagic cystitis; partially prevented by meson (binds to toxic metabs)